Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 705 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 705 shares of the firm’s stock in a transaction that occurred on Thursday, April 25th. The shares were sold at an average price of $89.55, for a total transaction of $63,132.75. Following the completion of the transaction, the chief financial officer now directly owns 71,397 shares of the company’s stock, valued at approximately $6,393,601.35. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, April 23rd, Michael Burkes Brophy sold 1,523 shares of Natera stock. The shares were sold at an average price of $91.38, for a total value of $139,171.74.
• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The stock was sold at an average price of $92.62, for a total value of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The shares were sold at an average price of $90.42, for a total value of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The stock was sold at an average price of $88.36, for a total value of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The shares were sold at an average price of $70.03, for a total transaction of $2,383,050.87.
• On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The shares were sold at an average price of $67.73, for a total transaction of $1,509,092.13.
• On Monday, January 29th, Michael Burkes Brophy sold 3,235 shares of Natera stock. The stock was sold at an average price of $65.09, for a total transaction of $210,566.15.

Natera Trading Up 0.4 %

Shares of Natera stock opened at $91.66 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10. The company has a market capitalization of $11.20 billion, a P/E ratio of -24.18 and a beta of 1.37. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $98.82. The company’s fifty day moving average is $88.16 and its two-hundred day moving average is $67.50.

Natera (NASDAQ:NTRA) last announced its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.09. The business had revenue of $311.11 million during the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. Analysts forecast that Natera, Inc. will post -2.35 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC grew its position in Natera by 224.4% in the 3rd quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock valued at $58,000 after buying an additional 911 shares during the last quarter. Ellsworth Advisors LLC acquired a new position in shares of Natera during the third quarter worth about $364,000. Xponance Inc. raised its holdings in Natera by 1.8% during the third quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock worth $642,000 after purchasing an additional 261 shares in the last quarter. Brown Advisory Inc. raised its holdings in Natera by 9.2% during the third quarter. Brown Advisory Inc. now owns 4,738 shares of the medical research company’s stock worth $210,000 after purchasing an additional 400 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Natera by 19.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,616 shares of the medical research company’s stock worth $912,000 after purchasing an additional 3,384 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a report on Tuesday, April 23rd. Canaccord Genuity Group upped their price target on Natera from $87.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, February 29th. Craig Hallum started coverage on shares of Natera in a research note on Monday, April 8th. They issued a “buy” rating and a $117.00 price target on the stock. Raymond James downgraded shares of Natera from a “strong-buy” rating to an “outperform” rating and boosted their price objective for the stock from $68.00 to $85.00 in a research report on Tuesday, February 20th. Finally, Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price on the stock in a research report on Friday, April 5th. One investment analyst has rated the stock with a sell rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.40.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.